501439-14-1

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-8-isopentyl-7-methyl-7,8-dihydropteridin-6(5H)-one is utilized as a precursor in the synthesis of various pteridine derivatives, which possess potential biological activities. These derivatives may act as antifolates or antineoplastic agents, contributing to the development of new therapeutic agents for treating diseases.
Used in Biomedical Research:
Leucopterin has been studied for its potential application as a fluorescent probe, capitalizing on its chemical structure and properties. This role allows researchers to explore its use in diagnostic tools and imaging techniques, enhancing the visualization and understanding of biological processes.

InChI:InChI=1/C12H17ClN4O/c1-7(2)4-5-17-8(3)11(18)15-9-6-14-12(13)16-10(9)17/h6-8H,4-5H2,1-3H3,(H,15,18)

Upstream product

• 1435462-61-5 methyl N-(2-chloro-5-nitropyrimidin-4-yl)-N-(3-methylbutyl)alaninate 
• 1435462-60-4 methyl N-(3-methylbutyl)alaninate 
• 590-86-3 isovaleraldehyde 
• 4462-17-3 N-phenylmethyl-N-3-methylbutaneamine 
• 107-82-4 i-pentyl bromide 

Downstream Products

• 1435462-62-6 2-chloro-7-methyl-8-(3-methylbutyl)-5-phenyl-7,8-dihydropteridin-6(5H)-one 
• 1435451-61-8 2-(1H-indazol-5-ylamino)-7-methyl-8-(3-methylbutyl)-5-phenyl-7,8-dihydropteridin-6(5H)-one 

Relevant academic research and scientific papers

Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study

The activity of p90 ribosomal S6 kinase 2 (RSK2) has emerged as an attractive target for cancer therapy due to its role in the regulation of diverse cellular processes, such as cell transformation and proliferation. Several pan-RSK inhibitors have been identified with BI-D1870 and the pseudo-analogs LJH685 and LJI308 being the most selective, potent, and frequently used small molecule inhibitors. We designed and synthesized a series of pteridinones and pyrimidines to evaluate the structural features of BI-D1870 that are required for RSK2 inhibition. We have identified inhibitors of RSK2 activity, evaluated their target engagement in cells, and measured their effect on cell viability and cytotoxicity in the MOLM-13 acute myeloid leukemia (AML) cell line. The results of our studies support that RSK2 inhibition can be achieved in MOLM-13 cells without potent cytotoxicity. The structure-activity data from this study will be used as a platform to develop novel RSK2 inhibitors.

DIHYDROPTERIDINONES

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at